Spots Global Cancer Trial Database for first time in human
Every month we try and update this database with for first time in human cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795 | NCT00920257 | Cancer | GSK2141795 | 18 Years - | GlaxoSmithKline | |
| Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma | NCT00536835 | Lymphoma, Non-H... | GSK461364 | 18 Years - | GlaxoSmithKline | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | NCT01966445 | Cancer Neoplasms | GSK2849330 | 18 Years - | GlaxoSmithKline | |
| Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma | NCT00536835 | Lymphoma, Non-H... | GSK461364 | 18 Years - | GlaxoSmithKline | |
| A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors | NCT00880321 | Cancer | GSK2118436 GSK2118436 Midazolam | 18 Years - | GlaxoSmithKline | |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | NCT04504669 | Clear Cell Rena... Non-Small-Cell ... Triple Negative... Squamous Cell C... Small Cell Lung... Gastroesophagea... Melanoma Cervical Cancer Advanced Solid ... | AZD8701 Durvalumab | 18 Years - 101 Years | AstraZeneca | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | NCT01966445 | Cancer Neoplasms | GSK2849330 | 18 Years - | GlaxoSmithKline | |
| Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers | NCT00996671 | Cancer | GSK2256098 Placebo | 18 Years - 65 Years | GlaxoSmithKline | |
| A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors | NCT03843359 | Neoplasms | GSK3745417 Dostarlimab | 18 Years - | GlaxoSmithKline | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers | NCT00996671 | Cancer | GSK2256098 Placebo | 18 Years - 65 Years | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
